Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immunicum AB: Invitation to Investor Events | |||
By: Nasdaq / GlobeNewswire - 22 Nov 2017 | Back to overview list |
||
Press releaseNovember 22, 2017 Invitation to Investor EventsImmunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events.
Aktiespararna Stora Aktiedagen in Gothenburg
Immunicum Investor Event in Stockholm
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Investor relations, sweden
Helena Stångberg
Investor and Media Relations EU/US
Gretchen Schweitzer
The Company's Certified Adviser is Redeye AB
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Immunicum AB via GlobeNewswire
HUG#2151271
|
|||
|
|||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |